Back to top
more

Sana Biotechnology (SANA)

(Real Time Quote from BATS)

$5.94 USD

5.94
353,268

-0.21 (-3.42%)

Updated Jul 30, 2024 01:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for SANA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

Sana Biotechnology, Inc. [SANA]

Reports for Purchase

Showing records 1 - 14 ( 14 total )

Company: Sana Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

06/17/2024

Daily Note

Pages: 6

EULAR Recap: Autologous CD19 CAR-T Results Establish Early Benchmarks for Cell Therapies in Autoimmune Diseases

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 25.00

Research Provided by a Third Party

Company: Sana Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

05/09/2024

Company Report

Pages: 5

1Q24 Recap: Four Clinical Programs on Track for Data in 2024

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Sana Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

03/01/2024

Company Report

Pages: 5

4Q23 Recap: Clinical Data in Several Indications Expected in 2024 Could Further Validate the Platform

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 10.00

Research Provided by a Third Party

Company: Sana Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

01/31/2024

Daily Note

Pages: 114

2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: Sana Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

01/30/2024

Daily Note

Pages: 115

2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: Sana Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

01/16/2024

Company Report

Pages: 8

Hypoimmune POC Established With Positive Efficacy and Safety; Upgrading to Buy With $12 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 25.00

Research Provided by a Third Party

Company: Sana Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

12/04/2023

Company Report

Pages: 4

First Patient Dosed in ARDENT Study Achieved PR; Additional Data to Be Announced in 2024; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: Sana Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

11/09/2023

Company Report

Pages: 5

3Q23 Recap: Attention Is on ARDENT Data in 4Q23 and Early IST Data in T1D

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: Sana Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

10/11/2023

Company Report

Pages: 6

Pipeline Reprioritization Puts Focus on Hypoimmune-Based Therapies; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 12.50

Research Provided by a Third Party

Company: Sana Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

08/04/2023

Company Report

Pages: 5

2Q23 Recap: Focus Remains on ARDENT Data in 2H23 That Could Provide Platform Validation

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: Sana Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

05/24/2023

Company Report

Pages: 5

RD Day Takeaways: Potential For Two Programs to Achieve Clinical Proof of Concept in 2023; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: Sana Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

05/09/2023

Company Report

Pages: 5

1Q23 Take: SC291 Phase 1 Study is Enrolling Patients With Initial Data Expected 2H23; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: Sana Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

05/02/2023

Company Report

Pages: 75

The Autologous CAR-T Therapy Pioneers Have Turned Allogeneic; Initiating at Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 75.00

Research Provided by a Third Party

Company: Sana Biotechnology, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for SANA

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party
// eof